Independent report · Private Markets

ChrysCapital and Novartis India: open offer at ₹860.64

· By Anurag

Novartis building signage; Novartis AG is the seller of Novartis India · Image: Medical Dialogues

Novartis building signage; Novartis AG is the seller of Novartis India · Image: Medical Dialogues

Independent report content

TARGETNovartis India Ltd, the BSE-listed commercial arm of Novartis in India
SELLERNovartis AG, selling its entire 70.68% (1,74,50,680 shares)
BUYERSWaveRise Investments 56.45% · ChrysCapital Fund X 10.32% · Two Infinity Partners 3.91% (Medical Dialogues; Business Today names five buyers, also including ChrysCapital X, LLC and OceanEdge Investments)
PRICEAbout ₹1,446 Cr · WaveRise at ₹860.64 a share · Fund X and Two Infinity at ₹701.25 (Outlook Business; not confirmed elsewhere)
OPEN OFFER26% (64,19,608 shares) at ₹860.64, up to ₹552.49 Cr · letter of offer 1 Jun 2026 · market price ₹1,351.20 on 4 Jun
TENDERS10 shares by 19 Jun, 182 by 24 Jun · one source says 40 accepted (single source)
TARGET FINANCIALSFY25 (March) revenue from operations ₹356.27 Cr · profit after tax ₹100.90 Cr
STATUSCompletion was expected in Q3 2026 and is not confirmed in the sources read
THE ACCESS POINT Novartis India is listed on BSE and NSE and can be bought in the market. ChrysCapital's own funds are open only to qualified investors.

Executive decision summary

THE BOTTOM LINENovartis AG agreed on 19 and 20 February 2026 to sell its entire 70.68% of Novartis India to a consortium of WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners for about ₹1,446 crore, about US$159 million. The research brief for this note gave July 2026; every source read dates the agreement to February. The deal forced an open offer for 26% at ₹860.64 a share, which was only 3.6% above the 19 February close and well below the ₹1,351 market price seen in June, so almost nobody tendered: 182 shares by 24 June. The company is small, with FY25 profit of ₹100.90 crore and reported bank balances of several hundred crore (from a search snippet). The buyers say they will not delist. Completion was expected in the third quarter of 2026 and is not confirmed in the sources read.
WHICH INVESTORThe deal fits a pharma-sector watcher IF you track multinational exits from Indian listed units and private equity taking control of legacy brands. Wait IF you need the completion date, the final open-offer count or FY26 profit explained: none was confirmed.
COMFORT FITCarve-out = a multinational sells its local listed business but keeps its global research and other units. Open offer = after a buyer takes control, it must offer to buy another 26% from public shareholders at a set price. Legacy brands = older established medicines such as Voveran and Calcium Sandoz, steady but not fast-growing. Tendering = a shareholder sells into the open offer. When the market price is higher, almost no one does.
THE RUPEIA NUMBER₹860.64. The price per share paid by WaveRise and offered to the public, against ₹1,351.20 in the market on 4 June 2026.

1 CLAIM REGISTER: EVIDENCE GRADING

ClaimSourceGradeRupeia assessment
Novartis AG sells entire 70.68% (1,74,50,680 shares) for about ₹1,446 CrBusiness Today; Medical DialoguesBEstablished
WaveRise 56.45%, Fund X 10.32%, Two Infinity 3.91%Medical DialoguesCEstablished; single detailed source
Open offer 26% at ₹860.64, up to ₹552.49 CrBusiness Today; Medical DialoguesBEstablished
Fund X and Two Infinity paid ₹701.25Outlook Business onlyDReconciles with the ₹1,446 Cr total, but needs the SPA filing
Agreement dated 19–20 Feb 2026; completion expected Q3 2026Business Today; Medical DialoguesBEstablished; completion not confirmed
Open-offer tenders: 10 to 182 shares; 40 acceptedWhalesbook; ScanX (40 accepted, single source)DOfficial acceptance filing not found
Q3 FY26 profit ₹525.6 CrSearch snippet onlyDUnverified and unexplained

2 THE DEAL AND HOW THE PRICE ADDS UP

ItemDetail
Stake sold70.68%, 1,74,50,680 shares, the whole Novartis AG holding
BuyersWaveRise Investments 56.45%; ChrysCapital Fund X 10.32%; Two Infinity Partners 3.91%
Other termsCompany to drop seller-group references from its name within 120 days of completion; non-recourse warranties; company to help with the open offer
DelistingAcquirers say they do not intend to delist and will meet minimum public shareholding norms
Why Novartis soldStrategic review since February 2024; focus on innovative medicines and a simpler global structure
Not soldNovartis Healthcare Pvt Ltd (more than 9,000 staff, Hyderabad R&D) is not part of the sale
Calculation (Rupeia)Result
Total shares in the company1,74,50,680 ÷ 70.68% ≈ 2.469 crore
WaveRise parcel56.45% × 2.469 crore ≈ 1.394 crore shares × ₹860.64 ≈ ₹1,199 Cr
Fund X and Two Infinity parcel(10.32% + 3.91%) × 2.469 crore ≈ 0.351 crore shares × ₹701.25 ≈ ₹246 Cr
Total₹1,199 Cr + ₹246 Cr ≈ ₹1,445.9 Cr, matching the ₹1,445.89 Cr reported
Open offer check64,19,608 shares × ₹860.64 = ₹552.5 Cr, matching the maximum
Dollar rate implied₹1,446 Cr ÷ US$159m ≈ ₹91 per US$
RUPEIA READ The two prices that looked contradictory in the sources fit together. The part of the stake bought by WaveRise carried the open-offer price of ₹860.64 and the smaller parcels bought by Fund X and Two Infinity carried ₹701.25, and the total matches the reported ₹1,446 crore to within ₹1 crore. That supports the Outlook Business figure, although the SPA disclosure itself was not opened.

3 THE OPEN OFFER: WHY NOBODY TENDERED

DateFactSource
19 Feb 2026Close ₹830.45; offer price ₹860.64 is a 3.64% premiumBusiness Today
20 Feb 2026Shares rose about 20% to the upper circuit, traded about ₹976 before the haltOutlook Business
1 Jun 2026Letter of offer datedWhalesbook
4 Jun 2026Market price ₹1,351.20 against the offer at ₹860.64Whalesbook
19 Jun 202610 physical shares tendered, none in demat formWhalesbook
24 Jun 2026182 physical shares tendered (BSE disclosure per search snippets)Whalesbook; snippets
10 Jul 202640 shares accepted from 182 tendered; acquirer holding 1,74,50,720 sharesScanX; single source
Calculation (Rupeia)Result
Market price against offer price, 4 Jun₹1,351.20 ÷ ₹860.64 − 1 = 57% above the offer
Tenders against the offer size182 ÷ 64,19,608 = 0.003%
Value of 100% at the offer price2.469 crore × ₹860.64 ≈ ₹2,125 Cr
Value of 100% at ₹1,351.202.469 crore × ₹1,351.20 ≈ ₹3,336 Cr
Offer price ÷ FY25 profit₹2,125 Cr ÷ ₹100.90 Cr ≈ 21x
RUPEIA READ An open offer priced 57% below the market is not meant to be taken up, so public holders kept their shares and the acquirers ended with essentially their negotiated 70.68% plus a handful of shares. For ordinary shareholders the real change is that control moved to ChrysCapital, not that they had to decide. Free float stays close to 29%.

4 WHAT THE COMPANY EARNS

MeasureValueSource quality
FY25 revenue from operations₹356.27 CrBusiness Today
FY25 total income₹398.23 CrBusiness Today
FY25 profit after tax₹100.90 CrBusiness Today
FY24 revenue and profit₹335 Cr and ₹85 CrSearch snippet
Cash and bank balancesAbout ₹52.07 Cr cash plus ₹595.96 Cr other bank balancesSearch snippet; layout inferred
Q3 FY26 revenue and profit₹411.8 Cr and ₹525.6 CrSearch snippet; unexplained
BrandsVoveran, Calcium range, Methergine (sold with Dr Reddy's); transplant range including Simulect, Certican, Sandimmun, Neoral and MyforticCompany and snippets
Calculation (Rupeia)Result
FY25 profit margin on total income₹100.90 Cr ÷ ₹398.23 Cr = 25.3%
Revenue growth FY24 to FY25₹356.27 Cr ÷ ₹335 Cr − 1 = 6.3%
Profit growth FY24 to FY25₹100.90 Cr ÷ ₹85 Cr − 1 = 18.7%
Value at the offer price less reported cash (if the snippet is right)₹2,125 Cr − ₹648 Cr ≈ ₹1,477 Cr, about 14.6x FY25 profit

The Q3 FY26 figure of ₹525.6 crore profit on ₹411.8 crore revenue would be five times the FY25 annual profit. It appears only in a search snippet and is unexplained, so it is not used in any calculation. It could reflect an exceptional gain, but the sources read do not say.

RUPEIA READ A 25% margin and a steady, brand-led portfolio explain the interest. A low growth rate of about 6% on revenue explains why the multiple is modest. The unexplained quarterly profit and the cash balance are the two items that would change the valuation most, and both need the annual report or exchange filings.

5 THE BUYERS AND THE CARVE-OUT PATTERN

ItemDetail
ChrysCapital Fund XFinal close US$2.2bn announced 5 Nov 2025, within six months of first close; described as the largest PE fund raised by an India-focused firm
ChrysCapital Fund IXUS$1.35bn, closed in 2022
Firm recordMore than US$5.5bn deployed across 110 portfolio companies; sectors consumer, healthcare, financial services, enterprise technology and industrial
PeopleKunal Shroff (Managing Partner and CEO), Sanjay Kukreja (Partner and CIO) and Sudip Nandy (Managing Director and Operating Partner), from search snippets only
PatternCommentary frames the sale as separating legacy product portfolios from innovation R&D; analyst Salil Kallianpur: "This is not Novartis exiting India."
RUPEIA CALCULATION Fund X at US$2.2bn is 2.2 ÷ 1.35 − 1 = 63% larger than Fund IX. The Novartis India deal of about US$159m is 159 ÷ 2,200 = 7.2% of Fund X, though part of the money came from WaveRise and Two Infinity, not from Fund X alone, so the Fund X share is smaller.
RUPEIA READ A consortium structure, with WaveRise taking more than four-fifths of the stake, means the deal is not a pure Fund X purchase. Who is behind WaveRise and Two Infinity was not found. For an investor in ChrysCapital funds, the unknown is how much of the exposure sits in Fund X.

6 RISKS, SCENARIOS AND CHECKLIST

RiskEvidenceSeverityKill condition
Brand and distribution termsNo royalty or licence disclosure found; Dr Reddy's distribution for some brandsMEDIUMBrand rights or licence fees surface
Earnings clarityQ3 FY26 profit unexplained; cash figure from a snippetMEDIUMProfit proves one-off
CompletionExpected Q3 2026; not confirmed in sources readLOWApprovals delayed
Minority holdersFree float about 29%; open offer priced below marketMEDIUMFloat rules force a sell-down
GrowthRevenue growth about 6% in FY25MEDIUMPortfolio erosion
Name changeMust drop seller-group references within 120 days of completionLOWBrand confusion
ScenarioWhat happensOutcome
BullNew owners add products and distribution; margin holdsEarnings grow above 6%
BaseSteady brands; cash returned over timeStable earnings
BearLegacy brands erode and licensing costs appearProfit falls
Investor classFitWhy
Long-term listed-market investorPARTIALCash-rich and profitable, but low growth and unexplained quarterly profit
ChrysCapital fund investorINFORMATIONALShows deal style: control of mature listed units
Short-term traderLOWOpen offer is closed; float is thin

Rupeia does not recommend buying or selling any security and is not a SEBI-registered investment adviser or research analyst. The open items are the completion date, the final open-offer count and the cash and Q3 profit figures.

7 KEY TERMS USED IN THIS REPORT

The terms below are used in this report. Each is explained in plain words.

TermMeaning
Open offerA mandatory offer to public shareholders to buy a further 26% after control changes hands.
SPAShare purchase agreement between buyer and seller.
Carve-outA multinational sells a local unit while keeping its other businesses.
Minimum public shareholdingRule that at least 25% of a listed company must be held by the public.
Upper circuitThe maximum a share may rise in a day under exchange rules.
Legacy brandsOlder, established medicines with steady but slow-growing sales.

Frequently asked questions

What did ChrysCapital buy?

A consortium of WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners agreed to buy Novartis AG's entire 70.68% of Novartis India for about ₹1,446 crore.

When was the deal agreed?

The agreement is dated 19 February 2026 and was announced on 20 February. Completion was expected in the third quarter of 2026 and is not confirmed in the sources read.

What was the open offer price?

₹860.64 a share for 26% of the company, up to ₹552.49 crore. The market price was ₹1,351.20 on 4 June, so very few shares were tendered.

Will Novartis India be delisted?

The acquirers say they do not intend to delist and will meet minimum public shareholding norms.

What does Novartis India earn?

FY25 revenue from operations was ₹356.27 crore and profit after tax ₹100.90 crore, per Business Today.

Does Novartis leave India?

No. Novartis Healthcare, with more than 9,000 staff and Hyderabad R&D, is not part of the sale.

Source log

Business Today: Novartis India promoter to sell entire 70.68% stake, triggering open offer at ₹860.64

Business Today: Why is Novartis selling its listed India commercial arm

Medical Dialogues: Novartis AG to exit India arm in ₹1,446 Cr deal

Outlook Business: Novartis India hits upper circuit as Swiss parent exits

Whalesbook: Novartis India open offer, ₹860.64 price lags market price of ₹1,351.20

Whalesbook: Novartis India open offer sees minimal tenders as of June 19

Entrackr: ChrysCapital closes US$2.2bn Fund X

DISCLAIMER This document is published strictly for informational, educational and academic record-keeping purposes. The publisher is not a SEBI Registered Investment Adviser (RIA) or Research Analyst (RA). It does not constitute personal investment advice, a financial recommendation, or an offer or solicitation to buy, sell or subscribe to any securities. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.